Boosters targeting two COVID strains
Published 8:00 pm Friday, September 9, 2022
On Aug. 31, the FDA authorized the use of a bivalent mRNA vaccine for booster doses for those 12 years and older.
According to Piedmont Health District Director Dr. Maria Almond, these updated vaccines now are targeting the original COVID vaccine strain and the most recent omicron variants BA.4/BA.5 that are currently in high circulation.
In addition, on Sept. 1 the CDC recommended the updated bivalent vaccines as a booster: Pfizer-BioNTech for people ages 12 years and older and from Moderna for people ages 18 years and older.
“These updated boosters are authorized for use 2 months after completion of any primary vaccine series or 2 months after receipt of any prior booster.” Dr. Almond said.
How do the new vaccines work
According to a press release from the FDA the bivalent vaccines, contain two messenger RNA (mRNA) components of SARS-CoV-2 virus, one of the original strain of SARS-CoV-2 and the other one in common between the BA.4 and BA.5 lineages of the omicron variant of SARS-CoV-2.
The Moderna COVID-19 Vaccine, Bivalent, is authorized for use as a single booster dose in individuals 18 years of age and older. The Pfizer-BioNTech COVID-19 Vaccine, Bivalent, is authorized for use as a single booster dose in individuals 12 years of age and older. The monovalent COVID-19 vaccines that are authorized or approved by the FDA and have been administered to millions of people in the United States since December 2020 contain a component from the original strain of SARS-CoV-2.
What you need to know:
The authorized bivalent COVID-19 vaccines, or updated boosters, include an mRNA component of the original strain to provide an immune response that is broadly protective against COVID-19 and an mRNA component in common between the omicron variant BA.4 and BA.5 lineages to provide better protection against COVID-19 caused by the omicron variant.
The BA.4 and BA.5 lineages of the omicron variant are currently causing most cases of COVID-19 in the U.S. and are predicted to circulate this fall and winter. In June, the agency’s Vaccines and Related Biological Products Advisory Committee voted overwhelmingly to include an omicron component in COVID-19 booster vaccines.
For each bivalent COVID-19 vaccine, the FDA based its decision on the totality of available evidence, including extensive safety and effectiveness data for each of the monovalent mRNA COVID-19 vaccines, safety and immunogenicity data obtained from a clinical study of a bivalent COVID-19 vaccine that contained mRNA from omicron variant BA.1 lineage that is similar to each of the vaccines being authorized, and nonclinical data obtained using a bivalent COVID-19 vaccine that contained mRNA of the original strain and mRNA in common between the BA.4 and BA.5 lineages of the omicron variant.
Based on the data supporting each of these authorizations, the bivalent COVID-19 vaccines are expected to provide increased protection against the currently circulating omicron variant. Individuals who receive a bivalent COVID-19 vaccine may experience side effects commonly reported by individuals who receive authorized or approved monovalent mRNA COVID-19 vaccines.
With the authorization, the monovalent mRNA COVID-19 vaccines are not authorized as booster doses for individuals 12 years of age and older.
The agency will work quickly to evaluate future data and submissions to support authorization of bivalent COVID-19 boosters for additional age groups as we receive them.
Who is eligible to receive a single booster dose and when:
Individuals 18 years of age and older are eligible for a single booster dose of the Moderna COVID-19 Vaccine, Bivalent if it has been at least two months since they have completed primary vaccination or have received the most recent booster dose with any authorized or approved monovalent COVID-19 vaccine.
Individuals 12 years of age and older are eligible for a single booster dose of the Pfizer-BioNTech COVID-19 Vaccine, Bivalent if it has been at least two months since they have completed primary vaccination or have received the most recent booster dose with any authorized or approved monovalent COVID-19 vaccine.
The Piedmont Health District local departments anticipate being able to offer the new bivalent booster vaccines in all counties by Thursday, Sept 8.
Regular weekly immunization clinics are held at the local health departments from 8:30am-4pm, including Covid, flu, school, and travel vaccines. Call to schedule an appointment. Immunization clinic schedule is as follows:
Charlotte: Mondays, (434) 542-5251
Nottoway: Mondays, (434) 645-7595
Lunenburg: Tuesdays, (434) 696-2346
Prince Edward: Tuesdays, (434) 392-8187
Amelia: Wednesdays, (804) 561-2711
Cumberland: Thursdays, (804) 492-4661
Buckingham: Thursdays, (434) 969-4244